Litcius/Paper detail

Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GISTs) is Effective and Safe: Results from a Prospective Single-Center Study with 108 Patients

Stijn J. C. van der Burg, Deborah van de Wal, Evelyne Roets, Neeltje Steeghs, Johanna W. van Sandick, Martijn Kerst, Frits van Coevorden, Koen J. Hartemink, Xander A. A. F. A. Veenhof, Anne Miek Koenen, Nikki S. IJzerman, Winette T.A. van der Graaf, Yvonne Schrage, Winan J. van Houdt

2023Annals of Surgical Oncology16 citationsDOIOpen Access PDF

Topics & Concepts

MedicineGiSTImatinibNeoadjuvant therapySurgical oncologySingle CenterConfidence intervalOdds ratioInternal medicineImatinib mesylateProspective cohort studyStromal tumorOncologySurgeryGastroenterologyRadiologyStromal cellCancerBreast cancerMyeloid leukemiaGastrointestinal Tumor Research and TreatmentGastrointestinal disorders and treatmentsGastrointestinal Bleeding Diagnosis and Treatment
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GISTs) is Effective and Safe: Results from a Prospective Single-Center Study with 108 Patients | Litcius